{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_YjAJQgxDlFX6S-O02jj9jCrVbrwlY3CGgCg1FzPlvBs.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nif(typeof window.MathJax === \u0022undefined\u0022) window.MathJax = { menuSettings: { zoom: \u0022Click\u0022 } };\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_waP91NpgGpectm_6Y2XDEauLJ8WCSCBKmmA87unpp2E.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.googletagmanager.com\/gtag\/js?id=G-0K57TCX5BY\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\nwindow.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments)};gtag(\u0022js\u0022, new Date());gtag(\u0022set\u0022, \u0022developer_id.dMDhkMT\u0022, true);gtag(\u0022config\u0022, \u0022G-0K57TCX5BY\u0022, {\u0022groups\u0022:\u0022default\u0022,\u0022anonymize_ip\u0022:true});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022ac\u0022:{\u0022medrxiv;2025.02.13.25320514v1\u0022:{\u0022access\u0022:{\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022medrxiv;2025.02.13.25320514v1\u0022,\u0022apath\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022medrxiv\u0022}},\u0022processed\u0022:[\u0022highwire_math\u0022],\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022medrxiv;2025.02.13.25320514v1\u0022}]},\u0022instances\u0022:\u0022{\\u0022highwire_abstract_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:20,\\u0022height\\u0022:20,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-abstract-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-abstract-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022right center\\u0022,\\u0022my\\u0022:\\u0022left center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022shift\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter click \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_author_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-author-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-author-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022top center\\u0022,\\u0022my\\u0022:\\u0022bottom center\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}},\\u0022highwire_reflinks_tooltip\\u0022:{\\u0022content\\u0022:{\\u0022text\\u0022:\\u0022\\u0022},\\u0022style\\u0022:{\\u0022tip\\u0022:{\\u0022width\\u0022:15,\\u0022height\\u0022:15,\\u0022border\\u0022:1,\\u0022mimic\\u0022:\\u0022top center\\u0022,\\u0022offset\\u0022:0,\\u0022corner\\u0022:true},\\u0022classes\\u0022:\\u0022qtip-custom hw-tooltip hw-ref-link-tooltip qtip-shadow qtip-rounded\\u0022,\\u0022classes_custom\\u0022:\\u0022hw-tooltip hw-ref-link-tooltip\\u0022},\\u0022position\\u0022:{\\u0022at\\u0022:\\u0022bottom left\\u0022,\\u0022my\\u0022:\\u0022top left\\u0022,\\u0022viewport\\u0022:true,\\u0022adjust\\u0022:{\\u0022method\\u0022:\\u0022flip\\u0022}},\\u0022show\\u0022:{\\u0022event\\u0022:\\u0022mouseenter \\u0022,\\u0022solo\\u0022:true},\\u0022hide\\u0022:{\\u0022event\\u0022:\\u0022mouseleave \\u0022,\\u0022fixed\\u0022:1,\\u0022delay\\u0022:\\u0022100\\u0022}}}\u0022,\u0022qtipDebug\u0022:\u0022{\\u0022leaveElement\\u0022:0}\u0022,\u0022googleanalytics\u0022:{\u0022account\u0022:[\u0022G-0K57TCX5BY\u0022],\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackColorbox\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022\\\/\\\/cdn.jsdelivr.net\\\/qtip2\\\/2.2.1\\\/jquery.qtip.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u00220\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u0022https:\\\/\\\/www.googletagmanager.com\\\/gtag\\\/js?id=G-0K57TCX5BY\u0022:1,\u00221\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__dn-cpI1YtkU_iLHgA5WhlkxgYWyat_IxjF_B-WSYrpE__a9hIbt0eaZ7d5nhwnm2weG8R_2eXK4EvoOx9dOxouHE__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/cdn.jsdelivr.net\/qtip2\/2.2.1\/jquery.qtip.min.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/advagg_css\/css__HGACIFBlu2o05y3afvqlt5wrE_5Dn6MXsexfuEpeIwg__t4SOPxucAPoV3Os7g8dXqyMB1HRXQridRJ82X7nE33E__QrrGUc7CpljPR5Aph-ukPbcwtK4AWrHGwCEXJ_k1V_c.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-article-tab-full-text\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 data-highwire-cite-ref-tooltip-instance=\u0022highwire_reflinks_tooltip\u0022 class=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EAbstract\u003C\/h2\u003E\u003Cdiv id=\u0022sec-1\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-2\u0022\u003E\u003Cstrong\u003EBackground\u003C\/strong\u003E Prostate cancer (PCa) is the leading cause of cancer death among men in Sweden. Although PSA (prostate-specific antigen) testing to screen for prostate cancer is common, its use remains controversial. This debate is primarily fueled by its insufficient operating characteristics, resulting in many benign biopsies and overdiagnosis of indolent disease. The population-based diagnostic STHLM3 trial developed and validated the Stockholm3 test, demonstrating that the combined use of PSA and Stockholm3 can identify clinically significant PCa with higher specificity while retaining the same sensitivity as PSA alone. However, the long-term implications of screening with the combined use of PSA and Stockholm3 on mortality remain unknown.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-2\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-3\u0022\u003E\u003Cstrong\u003EAim\u003C\/strong\u003E This study aims to evaluate the effect of a one-time \u003Cem\u003Einvitation\u003C\/em\u003E for prostate cancer screening (using PSA and Stockholm3 test in combination) in men aged 50\u201369 living in Stockholm on prostate cancer mortality and all-cause mortality, as well as its effects on prostate cancer incidence, PSA testing, and biopsy rates. The research question investigated in this study (STHLM3-F\/U) concerns one of the pre-specified secondary outcomes of the original population-based diagnostic STHLM3 study (\u003Ca href=\u0022\/external-ref?link_type=ISRCTN\u0026amp;access_num=ISRCTN84445406\u0022 class=\u0022external-ref external-ref-type-isrctn\u0022\u003EISRCTN84445406\u003C\/a\u003E).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-3\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-4\u0022\u003E\u003Cstrong\u003ERandomization and Intervention\u003C\/strong\u003E The trial involves men aged 50 to 69 living in Stockholm at the moment of invitation and who did not have a prostate cancer diagnosis. Randomization occurred at the population level using registry-based information, eligible men were randomly assigned to receive an invitation for screening or to continue with standard care. Invited men who decided to participate in the STHLM3 trial took a PSA test, followed by the Stockholm3 test if PSA level was above 1 ng\/mL. Systematic biopsy was recommended for those with PSA \u2265 3 ng\/mL and\/or a Stockholm3 score \u2265 10%. The non-invited group did not receive any invitations and relied on standard care.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-4\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-5\u0022\u003E\u003Cstrong\u003EOutcomes and analysis\u003C\/strong\u003E Primary outcome was prostate cancer mortality. Secondary outcomes included all-cause mortality, prostate cancer incidence, PSA testing, and biopsy rates. Data will be analyzed using registry information, with primary analysis using follow-up data until 2023-12-31. Time to prostate cancer mortality will be analyzed using the Aalen-Johansen estimator. Cumulative risks at the end of the follow-up will be compared between the invited and non-invited groups by means of a Risk Ratio at an alpha level of 3.5%. Both intention-to-screen and compliance-adjusted analyses will be performed.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-5\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-6\u0022\u003E\u003Cstrong\u003EDiscussion\u003C\/strong\u003E This study aims to address the knowledge gap regarding the long-term effect of screening with PSA and Stockholm3 tests in combination and provide insights into its potential effects on preventing mortality. Understanding whether a systematic organized screening intervention, using a combination of PSA and Stockholm3 has any effect on mortality can help inform decisions on prostate cancer screening policies.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-6\u0022 class=\u0022subsection\u0022\u003E\u003Cp id=\u0022p-7\u0022\u003E\u003Cstrong\u003EEthics and dissemination\u003C\/strong\u003E Approval for ethical conduct has been obtained from the Stockholm regional ethics committee. Results will be shared through peer-reviewed publications.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-7\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E1. Introduction\u003C\/h2\u003E\u003Cp id=\u0022p-21\u0022\u003EThis STHLM3-F\/U protocol describes the background and planned analyses for the long-term follow-up of the STHLM3 prostate cancer diagnostic trial (\u003Ca href=\u0022\/external-ref?link_type=ISRCTN\u0026amp;access_num=ISRCTN84445406\u0022 class=\u0022external-ref external-ref-type-isrctn\u0022\u003EISRCTN84445406\u003C\/a\u003E)\u003Csup\u003E\u003Ca id=\u0022xref-ref-1-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-1\u0022\u003E1\u003C\/a\u003E\u003C\/sup\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022sec-8\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E1.1 Background and Rationale\u003C\/h3\u003E\u003Cp id=\u0022p-22\u0022\u003EProstate cancer is a common disease, affecting approximately 1 in 8 men in the Western world during their lifetime\u003Csup\u003E\u003Ca id=\u0022xref-ref-2-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-2\u0022\u003E2\u003C\/a\u003E\u003C\/sup\u003E. In Sweden, prostate cancer is the primary cause of cancer mortality in men, with more than 2000 deaths every year\u003Csup\u003E\u003Ca id=\u0022xref-ref-3-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-3\u0022\u003E3\u003C\/a\u003E\u003C\/sup\u003E. The disease imposes a substantial burden on the healthcare system, with more than 120,000 men in Sweden living with a prostate cancer diagnosis. While low-risk prostate cancers are associated with low mortality rates, more aggressive forms impose a marked risk of cancer mortality and account for the majority of prostate cancer related deaths. Screening aims to reduce mortality by identifying cancers at an early stage, before they develop to a point when curative treatment is no longer possible. For prostate cancer, screening has over the last 30 years primarily relied on the use of the prostate-specific antigen (PSA) test\u003Csup\u003E\u003Ca id=\u0022xref-ref-4-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-4\u0022\u003E4\u003C\/a\u003E\u003C\/sup\u003E. However, prostate cancer screening using PSA is controversial, due to high rates of detection of low-risk prostate cancer typically associated with overdiagnosis, as well as high rates of unnecessary biopsies (benign findings)\u003Csup\u003E\u003Ca id=\u0022xref-ref-5-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-5\u0022\u003E5\u003C\/a\u003E\u003C\/sup\u003E. Different diagnostic tests are available that could mitigate PSA limitations, like the Stockholm3 test. Recently, magnetic resonance imaging (MRI) has also been introduced to reduce diagnosis of clinically low-risk prostate cancer (typically regarded as overdiagnosis) and the number of men who undergo biopsy unnecessarily.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-9\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E1.2 The STHLM3 trial\u003C\/h3\u003E\u003Cp id=\u0022p-23\u0022\u003EThe population-based STHLM3 prostate cancer diagnostic study\u003Csup\u003E\u003Ca id=\u0022xref-ref-6-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E\u003C\/sup\u003E (\u003Ca href=\u0022\/external-ref?link_type=ISRCTN\u0026amp;access_num=ISRCTN84445406\u0022 class=\u0022external-ref external-ref-type-isrctn\u0022\u003EISRCTN84445406\u003C\/a\u003E) was conducted from May 2012 to January 2015 (the data lock for the primary analysis of the trial was done in December 2014\u003Csup\u003E\u003Ca id=\u0022xref-ref-6-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E\u003C\/sup\u003E; some invited participants joined the trial after this data lock and were included in a subsequent analysis\u003Csup\u003E\u003Ca id=\u0022xref-ref-7-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-7\u0022\u003E7\u003C\/a\u003E\u003C\/sup\u003E), and was a one-time intervention that used a combination of a PSA and a Stockholm3 test to screen for clinically significant prostate cancer (defined Gleason Score \u22657 using 10-12 core systematic biopsy). The Stockholm3 test is a prediction algorithm that uses clinical variables, plasma protein biomarkers, and a polygenic risk score\u003Csup\u003E\u003Ca id=\u0022xref-ref-6-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E,\u003Ca id=\u0022xref-ref-8-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-8\u0022\u003E8\u003C\/a\u003E\u003C\/sup\u003E (\u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E). The STHLM3 trial showed that the use of the Stockholm3 test, compared to PSA alone, can identify clinically significant prostate cancer with higher specificity while retaining the same sensitivity. Furthermore, the study showed that using the Stockholm3 model could reduce the number of men diagnosed with a Gleason Score 6 cancer and the number of men needing to undergo biopsy. The use of the Stockholm3 test serves as a more accurate method to find prevalent prostate cancers in a population of asymptomatic men. It should be noted that opportunistic PSA based screening was common in the population of men aged 50-69 years old in Stockholm at the time of the STHLM3 trial, with about one third of the men in the population (and two thirds among STHLM3 participants) having undergone at least one previous PSA test.\u003C\/p\u003E\u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/02\/14\/2025.02.13.25320514\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Conformation of the Stockholm3 test developed and used in the STHLM3 trial.\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1679292607\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;Conformation of the Stockholm3 test developed and used in the STHLM3 trial.\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 1.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/02\/14\/2025.02.13.25320514\/F1.medium.gif\u0022 width=\u0022440\u0022 height=\u0022258\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 1.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/02\/14\/2025.02.13.25320514\/F1.medium.gif\u0022 width=\u0022440\u0022 height=\u0022258\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/02\/14\/2025.02.13.25320514\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 1.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/02\/14\/2025.02.13.25320514\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 1.\u003C\/span\u003E \u003Cp id=\u0022p-24\u0022 class=\u0022first-child\u0022\u003EConformation of the Stockholm3 test developed and used in the STHLM3 trial.\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-25\u0022\u003EIn the STHLM3 trial, eligible men (age 50 to 69 and residing in the Stockholm area with a permanent postal address, without previous prostate cancer diagnosis) were randomly assigned to either receive an invitation to undergo a single prostate cancer test (i.e. a combination of PSA and Stockholm3) or to not be invited and to continue with usual standard of care (\u003Ca id=\u0022xref-fig-2-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFigure 2\u003C\/a\u003E).\u003C\/p\u003E\u003Cdiv id=\u0022F2\u0022 class=\u0022fig pos-float type-figure  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/02\/14\/2025.02.13.25320514\/F2.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022CONSORT diagram\u0022 class=\u0022highwire-fragment fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1679292607\u0022 data-figure-caption=\u0022\u0026lt;div class=\u0026quot;highwire-markup\u0026quot;\u0026gt;CONSORT diagram\u0026lt;\/div\u0026gt;\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cspan class=\u0022hw-responsive-img\u0022\u003E\u003Cimg class=\u0022highwire-fragment fragment-image lazyload\u0022 alt=\u0022Figure 2.\u0022 src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/02\/14\/2025.02.13.25320514\/F2.medium.gif\u0022 width=\u0022440\u0022 height=\u0022396\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-fragment fragment-image\u0022 alt=\u0022Figure 2.\u0022 src=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/02\/14\/2025.02.13.25320514\/F2.medium.gif\u0022 width=\u0022440\u0022 height=\u0022396\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u0022download-fig first\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/02\/14\/2025.02.13.25320514\/F2.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 2.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u0022new-tab last\u0022\u003E\u003Ca href=\u0022https:\/\/www.medrxiv.org\/content\/medrxiv\/early\/2025\/02\/14\/2025.02.13.25320514\/F2.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 2.\u003C\/span\u003E \u003Cp id=\u0022p-26\u0022 class=\u0022first-child\u0022\u003ECONSORT diagram\u003C\/p\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-27\u0022\u003EFrom the pool of eligible candidates, a random selection was made from the Swedish Population Register maintained by the Swedish Tax Agency, and these individuals were contacted via mail with an invitation to participate in the STHLM3 trial.\u003C\/p\u003E\u003Cp id=\u0022p-28\u0022\u003EFor the invited men who responded to the invitation, the STHLM3 screening intervention involved two sequential steps: initially, all participants underwent a PSA test. Those with a PSA value \u22651 ng\/mL then underwent the Stockholm3 test. Men with a PSA level \u22653 ng\/mL or a Stockholm3 value \u226510% (or both) were recommended to undergo systematic prostate biopsy (STHLM3 was conducted before the introduction of pre-biopsy MRI and targeted biopsy in the Stockholm Region).\u003C\/p\u003E\u003Cp id=\u0022p-29\u0022\u003EFollowing negative PSA\/Stockholm3 tests (i.e. a PSA \u0026lt;3 ng\/mL and a Stockholm3 test \u0026lt;10%), a recommendation of when to return for testing was sent to study participants by mail. The recommendation was based on individual test values (re-test in 6-10 years if PSA \u0026lt;1 ng\/mL, retest in 2 years if PSA \u22651 ng\/mL and PSA \u0026lt;3 ng\/mL and Stockholm3 test \u0026lt;10%). Everything else (including treatment if diagnosed) was left to standard follow-up and treatment management was conducted as standard of care through the healthcare system.\u003C\/p\u003E\u003Cp id=\u0022p-30\u0022\u003EThe comparison group did not receive any type of invitation and continued undergoing the usual standard of care (\u003Ca id=\u0022xref-fig-2-2\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFigure 2\u003C\/a\u003E). Standard of care in Stockholm involved prevalent opportunistic testing, with about 25% of the population aged 50-59 and 40% of aged 60-69 having undergone at least one PSA test in the two years before the STHLM3 trial\u003Csup\u003E\u003Ca id=\u0022xref-ref-9-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003E9\u003C\/a\u003E\u003C\/sup\u003E (and 66% of STHLM3 participants having undergone at least one previous PSA test before enrolling in the STHLM3 trial).\u003C\/p\u003E\u003Cp id=\u0022p-31\u0022\u003EThus, the STHLM3 study constituted of two nested interventions: (1) One randomized intervention where men were randomly assigned to receive by mail an invitation to undergo prostate cancer screening using the PSA and Stockholm3 test; and (2) One intervention using a paired screen-positive design where the test characteristics of the two tests (PSA and Stockholm3) were compared in men who were randomized to receive the STHLM3 screening invitation \u003Cem\u003Eand\u003C\/em\u003E who decided to participate (main analysis for this intervention was published in the Lancet Oncology in 2015\u003Csup\u003E\u003Ca id=\u0022xref-ref-6-4\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E\u003C\/sup\u003E). This protocol describes how we will investigate the long-term effects of the first intervention, i.e. the one-off invitation to prostate cancer screening using both PSA and Stockholm3 (STHLM3-F\/U).\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-10\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E2. Methods\u003C\/h2\u003E\u003Cdiv id=\u0022sec-11\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E2.1 STHLM3-F\/U research questions\u003C\/h3\u003E\u003Cp id=\u0022p-32\u0022\u003EThis study aims to evaluate the effect of a one-time \u003Cem\u003Einvitation\u003C\/em\u003E for prostate cancer screening (using PSA and Stockholm3 in combination) in men aged 50\u201369 living in Stockholm on prostate cancer-specific and all-cause mortality, as well as its effects on prostate cancer incidence, PSA testing, and biopsy rates.\u003C\/p\u003E\u003Cp id=\u0022p-33\u0022\u003EThe primary outcome of this study is prostate cancer mortality. Secondary outcomes will include all-cause mortality, prostate cancer incidence, distinguishing between subgroups based on Gleason Score at diagnosis. PSA and biopsy patterns in the two randomized groups will also be evaluated.\u003C\/p\u003E\u003Cp id=\u0022p-34\u0022\u003EAll endpoints will be collected using registry data\u003Csup\u003E\u003Ca id=\u0022xref-ref-9-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003E9\u003C\/a\u003E\u003C\/sup\u003E. The primary analysis will be conducted with follow-up data until 2023-12-31, with the possibility of repeating the analysis in the future (at 15 and 20 years of follow-up). More details about the follow-up are explained in Section 2.2.\u003C\/p\u003E\u003Cdiv id=\u0022sec-12\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003ESTHLM3-F\/U\u003C\/h4\u003E\u003Cul class=\u0022list-none\u0022 id=\u0022list-1\u0022\u003E\u003Cli id=\u0022list-item-1\u0022\u003E\u003Cp id=\u0022p-35\u0022\u003E\u003Cspan class=\u0022list-label\u0022\u003E- \u003C\/span\u003E\u003Cstrong\u003EPopulation (P):\u003C\/strong\u003E Men aged 50 to 69 living in Stockholm county, without a prior prostate cancer diagnosis.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-2\u0022\u003E\u003Cp id=\u0022p-36\u0022\u003E\u003Cspan class=\u0022list-label\u0022\u003E- \u003C\/span\u003E\u003Cstrong\u003EIntervention (I):\u003C\/strong\u003E A single invitation to screen for prostate cancer utilizing PSA and the Stockholm3 test in combination. If a man tested positive on either PSA \u2265 3 ng\/mL or Stockholm3 \u2265 10%, he was recommended to undergo standard systematic prostate biopsy.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-3\u0022\u003E\u003Cp id=\u0022p-37\u0022\u003E\u003Cspan class=\u0022list-label\u0022\u003E- \u003C\/span\u003E\u003Cstrong\u003EComparison (C):\u003C\/strong\u003E Unscreened standard care, where \u2018unscreened\u2019 means that men in the comparison group were not invited to the STHLM3 trial (a single screen for prostate cancer using PSA combined with Stockholm3). Many men in the control group however undergo opportunistic prostate cancer screening (according to standard of care at the time of the STHLM3 trial and during the follow-up time).\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-4\u0022\u003E\u003Cp id=\u0022p-38\u0022\u003E\u003Cspan class=\u0022list-label\u0022\u003E- \u003C\/span\u003E\u003Cstrong\u003EOutcome (O):\u003C\/strong\u003E\u003C\/p\u003E\u003Cul class=\u0022list-unord \u0022 id=\u0022list-2\u0022\u003E\u003Cli id=\u0022list-item-5\u0022\u003E\u003Cp id=\u0022p-39\u0022\u003EPrimary outcome: Prostate cancer mortality.\u003C\/p\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-6\u0022\u003E\u003Cp id=\u0022p-40\u0022\u003ESecondary outcomes: All-cause mortality, prostate cancer incidence, PSA and biopsy patterns.\u003C\/p\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/li\u003E\u003Cli id=\u0022list-item-7\u0022\u003E\u003Cp id=\u0022p-41\u0022\u003E\u003Cspan class=\u0022list-label\u0022\u003E- \u003C\/span\u003E\u003Cstrong\u003ETimeframe (T):\u003C\/strong\u003E Analysis conducted with follow-up until 2023-12-31, with the possibility of repeating the analysis at 15 and 20 years of follow-up.\u003C\/p\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-13\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E2.2 Randomization and follow-up\u003C\/h3\u003E\u003Cp id=\u0022p-42\u0022\u003EThe research question investigated in this study (STHLM3-F\/U) concerns one of the original secondary outcomes of the population-based diagnostic STHLM3 study, prespecified in the original statistical analysis plan\u003Csup\u003E\u003Ca id=\u0022xref-ref-6-5\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E\u003C\/sup\u003E.\u003C\/p\u003E\u003Cp id=\u0022p-43\u0022\u003EFor the STHLM3-F\/U intervention, randomization was conducted at the population level prior to invitation to the STHLM3 trial, meaning that the randomized intervention was \u201cinvitation to undergo a single prostate cancer screen using PSA and Stockholm3\u201d. The randomization ratio was 70%, and it was chosen to ensure an invited group size to guarantee enough men enrolling in the STHLM3 to ensure statistical power for the primary analysis published in Gr\u00f6nberg et al. 2015\u003Csup\u003E\u003Ca id=\u0022xref-ref-6-6\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E\u003C\/sup\u003E comparing test characteristics of PSA vs. the Stockholm3 test (see \u003Cem\u003EPredictive probability of success\u003C\/em\u003E Section for more details).\u003C\/p\u003E\u003Cp id=\u0022p-44\u0022\u003EMen were randomly invited based on their date of birth between May 2012 and November 2014. Randomization time (invitation date, which we define as time 0 of the follow-up) corresponds to when letters were sent out inviting them to participate in the screening study. Non-invited men were assigned an invitation date (which we denote as \u201cpseudo-invitation date\u201d) that matched the STHLM3 invitations. The pseudo-invitation date will be considered as time 0 for the non-invited men.\u003C\/p\u003E\u003Cp id=\u0022p-45\u0022\u003EAll randomized participants are monitored through national or regional registries. Follow-up information on baseline characteristics and the outcomes will require data collection from various registries, including Statistics Sweden, the National Board of Health and Welfare, the National Prostate Cancer Register, and the Stockholm Prostate Cancer Diagnostics Register\u003Csup\u003E\u003Ca id=\u0022xref-ref-9-3\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-9\u0022\u003E9\u003C\/a\u003E,\u003Ca id=\u0022xref-ref-10-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-10\u0022\u003E10\u003C\/a\u003E\u003C\/sup\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022sec-14\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003EPredictive probability of success\u003C\/h4\u003E\u003Cp id=\u0022p-46\u0022\u003EThe STHLM3 trial\u2019s sample size was determined to guarantee sufficient power for the primary analysis (published in 2015 in Gr\u00f6nberg et al., Lancet Oncology\u003Csup\u003E\u003Ca id=\u0022xref-ref-6-7\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E\u003C\/sup\u003E). Therefore, we conducted an additional power analysis for the primary outcome of STHLM3-F\/U using data collected at an interim monitoring after 6.5 years post-initiation of the STHLM3 trial (i.e. with a maximum of 6.5 years of follow-up)\u003Csup\u003E\u003Ca id=\u0022xref-ref-11-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003E11\u003C\/a\u003E\u003C\/sup\u003E. The power is a function of the number of events of the primary endpoint (prostate cancer mortality) and increases with follow-up time as the number events increase. We estimated the Bayesian predictive probability of success\u003Csup\u003E\u003Ca id=\u0022xref-ref-12-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-12\u0022\u003E12\u003C\/a\u003E\u003C\/sup\u003E (PPoS) to guide the timing of the primary analysis of STHLM3-F\/U, i.e. the time point when a sufficiently high number of prostate cancer deaths has occurred during follow-up to generate reasonably high statistical power for detecting a significant difference regarding the primary outcome of the trial\u003Csup\u003E\u003Ca id=\u0022xref-ref-13-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-13\u0022\u003E13\u003C\/a\u003E\u003C\/sup\u003E.\u003C\/p\u003E\u003Cp id=\u0022p-47\u0022\u003ESuccess with respect to the primary outcome of the trial is evaluated by the p-value for the two-sided alternative hypothesis \u003Cem\u003EH\u003C\/em\u003E\u003Csub\u003E1\u003C\/sub\u003E : \u003Cem\u003ERR\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003EPCM\u003C\/em\u003E\u003C\/sub\u003E \u2260 1 versus the null \u003Cem\u003EH\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E : \u003Cem\u003ERR\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003EPCM\u003C\/em\u003E\u003C\/sub\u003E = 1 calculated as \u003Cspan class=\u0022inline-formula\u0022 id=\u0022inline-formula-1\u0022\u003E\u003Cspan class=\u0022highwire-responsive-lazyload\u0022\u003E\u003Cimg src=\u0022data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/yH5BAEAAAAALAAAAAABAAEAAAIBRAA7\u0022 class=\u0022highwire-embed lazyload\u0022 alt=\u0022Embedded Image\u0022 data-src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2025\/02\/14\/2025.02.13.25320514\/embed\/inline-graphic-1.gif\u0022\/\u003E\u003Cnoscript\u003E\u003Cimg class=\u0022highwire-embed\u0022 alt=\u0022Embedded Image\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/highwire\/medrxiv\/early\/2025\/02\/14\/2025.02.13.25320514\/embed\/inline-graphic-1.gif\u0022\/\u003E\u003C\/noscript\u003E\u003C\/span\u003E\u003C\/span\u003E, where \u003Cem\u003ERR\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003EPCM\u003C\/em\u003E\u003C\/sub\u003E is the risk ratio for prostate cancer mortality at the end of the follow-up time period, \u003Cem\u003EASE\u003C\/em\u003E(\u003Cem\u003Elog\u003C\/em\u003E(\u003Cem\u003ERR\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003EPCM\u003C\/em\u003E\u003C\/sub\u003E)) is the asymptotic standard error for the \u003Cem\u003Elog\u003C\/em\u003E(\u003Cem\u003ERR\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003EPCM\u003C\/em\u003E\u003C\/sub\u003E) and \u03a6(\u00b7) is the standard normal cumulative distribution function (more details in Section 3.3). The alpha level used for the interim analysis was 2%\u003Csup\u003E\u003Ca id=\u0022xref-ref-11-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-11\u0022\u003E11\u003C\/a\u003E\u003C\/sup\u003E. Assuming an information fraction of \u224830%, the final analysis will be done at an alpha level of 3.5% to ensure that the overall type I error rate, accounting for both interim and final analyses, remains at 0.05\u003Csup\u003E\u003Ca id=\u0022xref-ref-14-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-14\u0022\u003E14\u003C\/a\u003E\u003C\/sup\u003E.\u003C\/p\u003E\u003Cp id=\u0022p-48\u0022\u003EResults from the interim analysis and the PPoS analysis were utilized to inform the selection of a specific time point for the final analysis, since the time point for the final comparison between the two invitation arms was only specified in the original STHLM3 study protocol to be between 10 and 15 years after study initiation\u003Csup\u003E\u003Ca id=\u0022xref-ref-6-8\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-6\u0022\u003E6\u003C\/a\u003E\u003C\/sup\u003E.\u003C\/p\u003E\u003Cp id=\u0022p-49\u0022\u003EAt the interim analysis, the crude cumulative risk of prostate cancer mortality (PCM) was compared between the two randomized groups at 6.5 years after invitation, and the difference in PCM risk was summarized by a risk ratio (RR) with the non-invited group as the referent. At the interim analysis 6.5 years after the initiation of the STHLM3 trial, the significance level \u03b1(6.5) was set to 0.02. The RR for PCM was 0.66 (98% CI: 0.41, 1.06), p=0.04, which favoured the invited group but did not reach alpha adjusted formal statistical significance.\u003C\/p\u003E\u003Cp id=\u0022p-50\u0022\u003EWe predicted the probability of observing a statistically significant RR at final analysis based on data gathered until 2018-12-31 (i.e. the data used in the 6.5 years interim analysis). Specifically, we estimated the PPoS by simulating scenarios of the final analysis, with follow-up until the end of 2022, 2023, and so on until 2027.\u003C\/p\u003E\u003Cp id=\u0022p-51\u0022\u003ESince the PPoS with final analysis at any time between 2022 and 2027 was deemed sufficiently high and robust across the modeling strategies evaluated, the decision to compare PCM risk using follow-up until 2023-12-31 was made by the statisticians and principal investigators of the STHLM3 trial. The PPoS at the final analysis with data until 2023-12-31 is projected to reach 80%, ranging from 80 to 95% based on the modeling strategy used in the analysis\u003Csup\u003E\u003Ca id=\u0022xref-ref-13-2\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-13\u0022\u003E13\u003C\/a\u003E\u003C\/sup\u003E .\u003C\/p\u003E\u003Cp id=\u0022p-52\u0022\u003EFor a comprehensive description of the PPoS calculation, readers are referred to \u003Ca href=\u0022https:\/\/doi.org\/10.48550\/arXiv.2412.15899\u0022\u003Ehttps:\/\/doi.org\/10.48550\/arXiv.2412.15899\u003C\/a\u003E.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-15\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E3. Statistical analysis\u003C\/h2\u003E\u003Cdiv id=\u0022sec-16\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E3.1 Descriptive analyses\u003C\/h3\u003E\u003Cdiv id=\u0022sec-17\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003ETrial flowchart\u003C\/h4\u003E\u003Cp id=\u0022p-53\u0022\u003EWe will summarize the flow of study participants in a CONSORT diagram (\u003Ca id=\u0022xref-fig-2-3\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFigure 2\u003C\/a\u003E), including the number of eligible and randomized men, as well as the number of men undergoing the intervention. Further elements may also be included in the diagram.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-18\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003EBaseline characteristics\u003C\/h4\u003E\u003Cp id=\u0022p-54\u0022\u003EDescriptive characteristics will be reported to describe the population, presenting characteristics by randomisation group. Continuous variables will be summarized with mean and\/or median and interquartile range, while categorical variables will be presented as counts and percentages. Variables of interest will include age, region of birth, civil status, educational level, income, prostate cancer family history, Charlson comorbidity index (CCI), and previous PSA testing or biopsy at invitation (baseline).\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-19\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E3.2 Analysis strategies\u003C\/h3\u003E\u003Cdiv id=\u0022sec-20\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003EEffectiveness of the screening invitation\u003C\/h4\u003E\u003Cp id=\u0022p-55\u0022\u003EThe main analyses will be conducted according to the intention-to-screen (ITS) principle, i.e. on all men included in the STHLM3-F\/U cohort (i.e. on all men who were randomized to be invited or not invited to STHLM3) regardless of whether the invited men participated in STHLM3 or not. The ITS analysis will therefore compare the two randomized groups, i.e. men invited to the screening intervention and men not invited. This analysis targets the \u003Cem\u003Eeffectiveness\u003C\/em\u003E of the screening invitation. All study outcomes, primary and secondary (see below), will be analyzed according to this principle.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-21\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003EEfficacy of the STHLM3 screening procedure\u003C\/h4\u003E\u003Cp id=\u0022p-56\u0022\u003EA secondary analysis will target the \u003Cem\u003Eefficacy\u003C\/em\u003E of the STHLM3 screening procedure. The aim is to estimate the effect in participants of the one-off screening using PSA and Stockholm3 test in combination, i.e. to compare the prostate cancer mortality risk (primary outcome; see below) in those men who received the STHLM3 invitation and chose to participate with the risk in those men randomly assigned to the non-invited group who would have participated if they had been invited.\u003C\/p\u003E\u003Cp id=\u0022p-57\u0022\u003EFirst, we will use the method proposed by Cuzick et al\u003Csup\u003E\u003Ca id=\u0022xref-ref-15-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-15\u0022\u003E15\u003C\/a\u003E\u003C\/sup\u003E, as done in other prostate cancer screening trials (ERSPC\u003Csup\u003E\u003Ca id=\u0022xref-ref-16-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-16\u0022\u003E16\u003C\/a\u003E\u003C\/sup\u003E, CAP\u003Csup\u003E\u003Ca id=\u0022xref-ref-17-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-17\u0022\u003E17\u003C\/a\u003E,\u003Ca id=\u0022xref-ref-18-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-18\u0022\u003E18\u003C\/a\u003E\u003C\/sup\u003E), to adjust for non-compliance to the screening procedure. We will then use regression standardization as an alternative statistical method that targets the same quantity. Briefly, we will fit separate flexible parametric survival models for STHLM3 participants and non-invited men including age, region of birth (Nordic country vs non Nordic country), civil status, educational level, income, family history of prostate cancer, Charlson comorbidity index (CCI \u2265 1 vs CCI = 0), and previous PSA or biopsy exposure (yes vs no) at invitation as covariates. We will then standardize the model-based predicted prostate cancer mortality risks (in the presence of death due to other causes as a competing event) to the empirical distribution of the covariates in those men who were invited and participated in STHLM3.\u003C\/p\u003E\u003Cp id=\u0022p-58\u0022\u003EThe validity of these two efficacy analyses depends on the assumptions underlying the two statistical methods described above. As a benchmark, we will analyze the efficacy of the STHLM3 screening procedure on all-cause mortality. Since there is no reason to expect long-term differences in terms of all-cause mortality between participants and the counterfactual group of non-invited men who would have participated if they had been invited, any meaningful difference resulting from the analyses would indicate that the assumptions may not be (fully) met.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-22\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E3.3 Primary outcome\u003C\/h3\u003E\u003Cp id=\u0022p-59\u0022\u003EProstate cancer mortality, a time-to-event endpoint, will be considered as the primary outcome. The prostate cancer mortality risk at the end of follow-up will be calculated from the cumulative incidence functions (CIF) using the nonparametric Aalen-Johansen estimator, taking into account the presence of other-cause mortality as a competing event. Risk ratios (\u003Cem\u003ERR\u003C\/em\u003E) will be calculated to compare the invitation groups at an alpha level of 3.5% against the null hypothesis \u003Cem\u003EH\u003C\/em\u003E\u003Csub\u003E0\u003C\/sub\u003E : \u003Cem\u003ERR\u003C\/em\u003E\u003Csub\u003E\u003Cem\u003EPCM\u003C\/em\u003E\u003C\/sub\u003E = 1 . A two-sided alternative hypothesis will be adopted because the possibility that a screening invitation might increase the risk of prostate cancer mortality cannot be excluded a priori. For calculating p-values and confidence intervals, the asymptotic standard error derived from delta method for the log risk ratio (ASE(log(\u003Cem\u003ERR\u003C\/em\u003E \u003Csub\u003E\u003Cem\u003EPCM\u003C\/em\u003E\u003C\/sub\u003E))) will be used. The non-invited group will be the reference group for the \u003Cem\u003ERR\u003C\/em\u003E.\u003C\/p\u003E\u003Cp id=\u0022p-60\u0022\u003EDate of invitation will be used as time 0. Follow-up time will be calculated as the time between the date of invitation and the date of the earliest event between death (from prostate cancer or from other causes, respectively), emigration outside Sweden, or end of follow-up (2023-12-31, administrative censoring).\u003C\/p\u003E\u003Cp id=\u0022p-61\u0022\u003EProstate cancer deaths will be identified using the National Cause of Death Register\u003Csup\u003E\u003Ca id=\u0022xref-ref-19-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-19\u0022\u003E19\u003C\/a\u003E\u003C\/sup\u003E, and all deaths with C61 as \u201cunderlying cause of death according to ICD-10\u201d will be considered prostate cancer deaths\u003Csup\u003E\u003Ca id=\u0022xref-ref-20-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-20\u0022\u003E20\u003C\/a\u003E\u003C\/sup\u003E.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-23\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E3.4 Secondary outcomes\u003C\/h3\u003E\u003Cp id=\u0022p-62\u0022\u003EFor secondary outcomes, point estimates and 95% confidence intervals in the two randomized groups will be presented, and may be compared using ratios.\u003C\/p\u003E\u003Cdiv id=\u0022sec-24\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003EAll-cause mortality\u003C\/h4\u003E\u003Cp id=\u0022p-63\u0022\u003EAll-cause mortality will be evaluated at the end of follow-up using non-parametric cumulative incidence functions, comparing groups using risk ratios. Date of invitation will be used as time 0. Follow-up time will be calculated as the time between the date of invitation and the first event between emigration outside Sweden, death or end of follow-up (administrative censoring).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-25\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003EProstate cancer incidence\u003C\/h4\u003E\u003Cp id=\u0022p-64\u0022\u003EIncidence of prostate cancer will be evaluated at the end of follow-up, overall (Gleason Score \u22656), and differentiating between Gleason Score 6 and Gleason Score \u22657. Incidence analyses will also be conducted based on Gleason Score at diagnosis, grouping cases into categories of GS 3+3, 3+4, 4+3, and \u22658. Incidence analyses will use the same method as for prostate cancer mortality, comparing groups with risk ratios. Death from any causes will be considered as a competing event.\u003C\/p\u003E\u003Cp id=\u0022p-65\u0022\u003EDate of invitation will be used as time 0. Follow-up time will be calculated as the time between the date of invitation and the first event between prostate cancer diagnosis, emigration outside Sweden, death or end of follow-up (administrative censoring).\u003C\/p\u003E\u003Cp id=\u0022p-66\u0022\u003ENon-missing Gleason Score information is required for the incidence analysis grouped by Gleason Score. Missing values will be imputed using Multivariate Imputation by Chained Equations (MICE)\u003Csup\u003E\u003Ca id=\u0022xref-ref-21-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-21\u0022\u003E21\u003C\/a\u003E\u003C\/sup\u003E with predictive mean matching (PMM) and a donor pool of k=5. Specifically, missing data for individual primary and secondary Gleason patterns (GS1 and GS2) will be imputed using age at invitation, date of diagnosis, and PSA at diagnosis as predictors. We will generate 1000 datasets with imputed outcome data, which will be analyzed separately. We will then use Rubin\u2019s rules to pool risks (and standard errors) of prostate cancer diagnosis in each group.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-26\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003EPSA and Biopsy patterns\u003C\/h4\u003E\u003Cp id=\u0022p-67\u0022\u003EThe fraction of men undergoing at least one PSA test and biopsy will be evaluated, as well as the cumulative number of tests performed during the follow-up. The mean number of PSA tests and biopsies per man over the follow-up period will also be estimated.\u003C\/p\u003E\u003Cp id=\u0022p-68\u0022\u003EOnly diagnostic PSA tests and biopsies will be considered, meaning tests conducted on men who are free of a prostate cancer diagnosis, excluding those tests taken to monitor diagnosed patients. All PSA tests performed before the date of prostate cancer diagnosis will be included. To account for potential delays in biopsy reporting, biopsies conducted up to 30 days after diagnosis will also be included. This 30-day time allowance permits sufficient reporting time, as recommended by clinician advisors, ensuring the inclusion of actual diagnostic biopsies.\u003C\/p\u003E\u003Cp id=\u0022p-69\u0022\u003EDate of invitation will be used as time 0. PSA tests and biopsies related to the intervention will be included in the analysis. Men will be followed until the first event between prostate cancer diagnosis (+30 days in the biopsy analysis), emigration, death, or end of follow-up (administrative censoring).\u003C\/p\u003E\u003Cp id=\u0022p-70\u0022\u003ETo estimate the mean number of tests per man over the follow-up period, we will use the marginal Ghosh and Lin non-parametric method accounting for competing events\u003Csup\u003E\u003Ca id=\u0022xref-ref-22-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-22\u0022\u003E22\u003C\/a\u003E\u003C\/sup\u003E, that will consist of mortality and prostate cancer diagnosis.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-27\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003EStockholm3 test\u003C\/h4\u003E\u003Cp id=\u0022p-71\u0022\u003ESince 2018 the use of the Stockholm3 test has been introduced in clinics across the Stockholm region. We may, depending on the availability of the data, report the use of the Stockholm3 test over the follow-up period. Proportion of men tested with the Stockholm3 test in each randomized group will be calculated, overall and stratified by year. Similar analysis as for the PSA test may be performed (see preceding section).\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-28\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E3.5 Additional analysis \u2013 different measures\u003C\/h3\u003E\u003Cp id=\u0022p-72\u0022\u003ESince STHLM3 is a one-time screen (i.e. the men were invited to screening only once), it is likely that any difference between the groups (i.e. men invited to STHLM3 vs. not) with respect to prostate cancer mortality will increase in the years following the intervention and then at some point start to decrease again. The reason why this is likely is that prevalent cases (cases present in the population at time of invitation, but yet undetected) will to a higher degree be detected in the intervention arm (i.e. among men invited to screening), however we do not expect large differences between the groups with respect to incident development of new cases \u003Cem\u003Eafter\u003C\/em\u003E the STHLM3 intervention. Eventually, the prostate cancer mortality from the incident cases detected after the STHLM3 intervention may start to dominate the total number of men who die due to prostate cancer, meaning that the difference in mortality between the groups may start to decrease again. Therefore, in addition to analyzing the risk ratio at the end of follow-up, we will also compute the risk ratio (and 95% confidence intervals) at additional time points (Section 3.7). Additionally, we may also compare groups using restricted mean time lost to evaluate different estimands of the effect of the intervention (randomization to receive an invitation to the STHLM3 screening trial vs. not). For the same reason, cause-specific hazard ratios from Cox models will be estimated.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-29\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E3.6 Subgroup analysis\u003C\/h3\u003E\u003Cp id=\u0022p-73\u0022\u003EWe will perform subgroup analyses by stratifying men based on age groups at the time of invitation (in 5-year strata) and educational level (low-mid-high) as a measure of socioeconomic status. Income may also be used for the same purpose as educational level.\u003C\/p\u003E\u003Cdiv id=\u0022sec-30\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003ESTHLM3 participants\u003C\/h4\u003E\u003Cp id=\u0022p-74\u0022\u003EWe may perform a subgroup analysis restricted to STHLM3 participants, to investigate potential heterogeneity within this group. Since the STHLM3 trial had a paired design, men could be referred to further diagnostic workup (biopsy) based on elevated PSA test (\u22653 ng\/mL), elevated Stockholm3 test (\u226510%), or both. The STHLM3 trial participants can be categorised based on their PSA and Stockholm3 value at screening into 4 risk groups: (+,+), (+,-), (-,+), (-,-). We may investigate mortality stratified over these four groups. We may also investigate mortality among participants based solely on PSA value at STHLM3 screening, for example by stratifying men into groups: PSA \u2264 1, between 1 and 2, between 2 and 3, and PSA \u22653 ng\/mL.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-31\u0022 class=\u0022subsection\u0022\u003E\u003Ch3\u003E3.7 Sensitivity analysis\u003C\/h3\u003E\u003Cdiv id=\u0022sec-32\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003EAnalysis without multiple imputation\u003C\/h4\u003E\u003Cp id=\u0022p-75\u0022\u003EWe will repeat the incidence analysis among different Gleason Score groups without imputation of missingness on Gleason Score.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-33\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003EAnalysis at different time points\u003C\/h4\u003E\u003Cp id=\u0022p-76\u0022\u003EThe main analysis will be performed at the end of available follow-up. We will repeat the analysis on mortality and incidence at different time points of interest over the follow-up period, by extracting risks from the cumulative incidence functions at specific time points (eg: 4, 6, 8, 10 years of follow-up).\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv id=\u0022sec-34\u0022 class=\u0022subsection\u0022\u003E\u003Ch4\u003ESTHLM3-MRI trial\u003C\/h4\u003E\u003Cp id=\u0022p-77\u0022\u003EThe STHLM3-MRI study (\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT03377881\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F14%2F2025.02.13.25320514.atom\u0022\u003ENCT03377881\u003C\/a\u003E)\u003Csup\u003E\u003Ca id=\u0022xref-ref-23-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-23\u0022\u003E23\u003C\/a\u003E\u003C\/sup\u003E has been ongoing in the Stockholm region since 2018\u003Csup\u003E\u003Ca id=\u0022xref-ref-24-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-24\u0022\u003E24\u003C\/a\u003E\u2013\u003Ca id=\u0022xref-ref-26-1\u0022 class=\u0022xref-bibr\u0022 href=\u0022#ref-26\u0022\u003E26\u003C\/a\u003E\u003C\/sup\u003E. In the STHLM3-MRI study, the Stockholm3 test was used together with the PSA test. We anticipate an increase in prostate cancer incidence during the years in which the trial was conducted due to the organized screening among the STHLM3-MRI participants.\u003C\/p\u003E\u003Cp id=\u0022p-78\u0022\u003EWe can retrieve information on the men invited to participate in the STHLM3-MRI trial and those who participated in the trial. We will conduct an analysis of mortality and incidence, excluding men invited to the STHLM3-MRI trial. Since these men were invited to participate in the STHLM3-MRI trial conditional on \u003Cem\u003Enot\u003C\/em\u003E having participated in the STHLM3 trial, their exclusion will break randomization in the STHLM-F\/U trial. We may account for this using statistical methods such as inverse probability of treatment weighting or regression standardisation.\u003C\/p\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-35\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E4. Discussion\u003C\/h2\u003E\u003Cp id=\u0022p-79\u0022\u003EThis study aims to address the knowledge gap regarding the long-term effect of screening with the Stockholm3 test, a diagnostic tool designed to improve upon the limitations of the traditional PSA test. It will provide a novel analysis of mortality data from men screened for prostate cancer using both PSA and Stockholm3 (a prediction model incorporating novel biomarkers, clinical variables, and a genetic risk score).\u003C\/p\u003E\u003Cp id=\u0022p-80\u0022\u003EThe design of the STHLM3 trial included two nested interventions: first a \u003Cem\u003Erandomized invitation\u003C\/em\u003E to the STHLM3 trial and then a \u003Cem\u003Epaired intervention\u003C\/em\u003E among those men who were invited to and participated in STHLM3 to assess the operating characteristics of the Stockholm3 test relative to those of the PSA test. The design with the two nested interventions allows us to use the randomized groups to evaluate the effects of the invitation. Understanding whether a systematic screening intervention, employing an approach to screening using both PSA and the Stockholm3 test, has any effect on mortality can help inform decisions on prostate cancer screening policies.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section data-availability\u0022 id=\u0022sec-36\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EData Availability\u003C\/h2\u003E\u003Cp id=\u0022p-81\u0022\u003EAll data used in this work are included in the manuscript. Since this manuscript describes a protocol, no outcome data has been collected yet.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-37\u0022\u003E\u003Ch2 class=\u0022\u0022\u003E5. Ethics\u003C\/h2\u003E\u003Cp id=\u0022p-82\u0022\u003EThe study protocol was approved by Stockholm regional ethics committee (permits 2012\/572-31\/1 and 2012\/438-31\/3). Written informed consent was obtained from all participants in the STHLM3 intervention.\u003C\/p\u003E\u003C\/div\u003E\u003Cdiv class=\u0022section ref-list\u0022 id=\u0022ref-list-1\u0022\u003E\u003Ch2 class=\u0022\u0022\u003EReferences\u003C\/h2\u003E\u003Col class=\u0022cit-list ref-use-labels\u0022\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E1.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-1-1\u0022 title=\u0022View reference 1. in text\u0022 id=\u0022ref-1\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.1\u0022 data-doi=\u002210.1016\/S1470-2045(15)00361-7\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGr\u00f6nberg\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAdolfsson\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAly\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EProstate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet Oncol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E16\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E16\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E1667\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1676\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1016\/S1470-2045(15)00361-7\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DLancet%2BOncol%26rft.volume%253D16%26rft.spage%253D1667%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS1470-2045%252815%252900361-7%26rft_id%253Dinfo%253Apmid%252F26563502%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/S1470-2045(15)00361-7\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=26563502\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F14%2F2025.02.13.25320514.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E2.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-2-1\u0022 title=\u0022View reference 2. in text\u0022 id=\u0022ref-2\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.2\u0022 data-doi=\u002210.1186\/s12916-015-0405-5\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELloyd\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHounsome\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMehay\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMee\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ES\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EVerne\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECooper\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ELifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008-2010\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBMC Med\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E13\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E171\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1186\/s12916-015-0405-5\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DBMC%2BMed%26rft.volume%253D13%26rft.spage%253D171%26rft_id%253Dinfo%253Adoi%252F10.1186%252Fs12916-015-0405-5%26rft_id%253Dinfo%253Apmid%252F26224061%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1186\/s12916-015-0405-5\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=26224061\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F14%2F2025.02.13.25320514.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E3.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-3-1\u0022 title=\u0022View reference 3. in text\u0022 id=\u0022ref-3\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.3\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EStatistics on Cancer Incidence 2021\u003C\/abbr\u003E. Published online 2022.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E4.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-4-1\u0022 title=\u0022View reference 4. in text\u0022 id=\u0022ref-4\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.4\u0022 data-doi=\u002210.1016\/j.eururo.2019.02.009\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EHugosson\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERoobol\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EM\u00e5nsson\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EA 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EEur Urol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2019\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E76\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E43\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E51\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1016\/j.eururo.2019.02.009\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DEur%2BUrol%26rft.volume%253D76%26rft.spage%253D43%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.eururo.2019.02.009%26rft_id%253Dinfo%253Apmid%252F30824296%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.eururo.2019.02.009\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=30824296\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F14%2F2025.02.13.25320514.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E5.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-5-1\u0022 title=\u0022View reference 5. in text\u0022 id=\u0022ref-5\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.5\u0022 data-doi=\u002210.14694\/EdBook_AM.2012.32.98\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EThompson\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EIM\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EOverdiagnosis and Overtreatment of Prostate Cancer\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EAm Soc Clin Oncol Educ Book\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2012\u003C\/span\u003E;(\u003Cspan class=\u0022cit-issue\u0022\u003E32\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003Ee35\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003Ee39\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.14694\/EdBook_AM.2012.32.98\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DAm%2BSoc%2BClin%2BOncol%2BEduc%2BBook%26rft_id%253Dinfo%253Adoi%252F10.14694%252FEdBook_AM.2012.32.98%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.14694\/EdBook_AM.2012.32.98\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E6.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-6-1\u0022 title=\u0022View reference 6. in text\u0022 id=\u0022ref-6\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.6\u0022 data-doi=\u002210.1016\/S1470-2045(15)00361-7\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGr\u00f6nberg\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAdolfsson\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAly\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EProstate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet Oncol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2015\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E16\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E16\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E1667\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1676\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1016\/S1470-2045(15)00361-7\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DLancet%2BOncol%26rft.volume%253D16%26rft.spage%253D1667%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS1470-2045%252815%252900361-7%26rft_id%253Dinfo%253Apmid%252F26563502%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/S1470-2045(15)00361-7\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=26563502\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F14%2F2025.02.13.25320514.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E7.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-7-1\u0022 title=\u0022View reference 7. in text\u0022 id=\u0022ref-7\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2025.02.13.25320514v1.7\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-source\u0022\u003EThe Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential - PubMed\u003C\/span\u003E. Accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003EDecember 2, 2024\u003C\/span\u003E. \u003Ca href=\u0022https:\/\/pubmed.ncbi.nlm.nih.gov\/29331214\/\u0022\u003Ehttps:\/\/pubmed.ncbi.nlm.nih.gov\/29331214\/\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E8.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-8-1\u0022 title=\u0022View reference 8. in text\u0022 id=\u0022ref-8\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.8\u0022 data-doi=\u002210.1016\/S1470-2045(21)00348-X\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENordstr\u00f6m\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDiscacciati\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBergman\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EProstate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ELancet Oncol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E22\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E9\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E1240\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1249\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1016\/S1470-2045(21)00348-X\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DLancet%2BOncol%26rft.volume%253D22%26rft.spage%253D1240%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS1470-2045%252821%252900348-X%26rft_id%253Dinfo%253Apmid%252F34391509%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/S1470-2045(21)00348-X\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=34391509\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F14%2F2025.02.13.25320514.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E9.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-9-1\u0022 title=\u0022View reference 9. in text\u0022 id=\u0022ref-9\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.9\u0022 data-doi=\u002210.1016\/j.eururo.2012.10.001\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENordstr\u00f6m\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAly\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EClements\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMS\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EWeibull\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ECE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAdolfsson\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGr\u00f6nberg\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EH.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EProstate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EEur Urol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2013\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E63\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E3\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E419\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E425\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1016\/j.eururo.2012.10.001\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DEur%2BUrol%26rft.volume%253D63%26rft.spage%253D419%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.eururo.2012.10.001%26rft_id%253Dinfo%253Apmid%252F23083803%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.eururo.2012.10.001\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=23083803\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F14%2F2025.02.13.25320514.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E10.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-10-1\u0022 title=\u0022View reference 10. in text\u0022 id=\u0022ref-10\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.10\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAbbadi\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EAhmad;\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEklund\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMartin;\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAly\u003C\/span\u003E,  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMarkus;\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ECohort Profile: STHLM0, the Stockholm Prostate Cancer Diagnostics Register\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EManuscript under revision\u003C\/abbr\u003E.\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E11.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-11-1\u0022 title=\u0022View reference 11. in text\u0022 id=\u0022ref-11\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.11\u0022 data-doi=\u002210.1016\/S0302-2838(23)00930-2\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMicoli\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECrippa\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDiscacciati\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EA0890 - The Stockholm3 prostate cancer screening trial (STHLM3): An interim analysis of mortality results after 6.5 years of follow-up\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EEur Urol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2023\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E83\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003ES1266\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003ES1267\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1016\/S0302-2838(23)00930-2\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DEur%2BUrol%26rft.volume%253D83%26rft.spage%253DS1266%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS0302-2838%252823%252900930-2%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/S0302-2838(23)00930-2\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E12.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-12-1\u0022 title=\u0022View reference 12. in text\u0022 id=\u0022ref-12\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.12\u0022 data-doi=\u002210.1016\/0197-2456(86)90003-6\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESpiegelhalter\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFreedman\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ELS\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBlackburn\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EPR\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EMonitoring clinical trials: Conditional or predictive power?\u003C\/span\u003E \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EControl Clin Trials\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E1986\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E7\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E1\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E8\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E17\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1016\/0197-2456(86)90003-6\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DControlled%2Bclinical%2Btrials%26rft.stitle%253DControl%2BClin%2BTrials%26rft.aulast%253DSpiegelhalter%26rft.auinit1%253DD.%2BJ.%26rft.volume%253D7%26rft.issue%253D1%26rft.spage%253D8%26rft.epage%253D17%26rft.atitle%253DMonitoring%2Bclinical%2Btrials%253A%2Bconditional%2Bor%2Bpredictive%2Bpower%253F%26rft_id%253Dinfo%253Adoi%252F10.1016%252F0197-2456%252886%252990003-6%26rft_id%253Dinfo%253Apmid%252F3956212%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/0197-2456(86)90003-6\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=3956212\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F14%2F2025.02.13.25320514.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=A1986A577800002\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E13.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-13-1\u0022 title=\u0022View reference 13. in text\u0022 id=\u0022ref-13\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.13\u0022 data-doi=\u002210.48550\/arXiv.2412.15899\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMicoli\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EC\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECrippa\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EConnor\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJT\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth cit-collab\u0022\u003EConsortium ISC\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEklund\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDiscacciati\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA.\u003C\/span\u003E\u003C\/span\u003E \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003ESimulation-based Bayesian predictive probability of success for interim monitoring of clinical trials with competing event data: two case studies\u003C\/abbr\u003E. Published online December 20, 2024.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.48550\/arXiv.2412.15899\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DSimulation-based%2BBayesian%2Bpredictive%2Bprobability%2Bof%2Bsuccess%2Bfor%2Binterim%2Bmonitoring%2Bof%2Bclinical%2Btrials%2Bwith%2Bcompeting%2Bevent%2Bdata%253A%2Btwo%2Bcase%2Bstudies%26rft_id%253Dinfo%253Adoi%252F10.48550%252FarXiv.2412.15899%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.48550\/arXiv.2412.15899\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E14.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-14-1\u0022 title=\u0022View reference 14. in text\u0022 id=\u0022ref-14\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.14\u0022 data-doi=\u002210.1002\/sim.4780131308\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDeMets\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELan\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EKK\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EInterim analysis: the alpha spending function approach\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EStat Med\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E1994\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E13\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E13-14\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E1341\u003C\/span\u003E-\u003Cspan class=\u0022cit-lpage\u0022\u003E1352\u003C\/span\u003E; discussion 1353-1356.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1002\/sim.4780131308\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DStatistics%2Bin%2Bmedicine%26rft.stitle%253DStat%2BMed%26rft.aulast%253DDeMets%26rft.auinit1%253DD.%2BL.%26rft.volume%253D13%26rft.issue%253D13-14%26rft.spage%253D1341%26rft.epage%253D1352%26rft.atitle%253DInterim%2Banalysis%253A%2Bthe%2Balpha%2Bspending%2Bfunction%2Bapproach.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fsim.4780131308%26rft_id%253Dinfo%253Apmid%252F7973215%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1002\/sim.4780131308\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=7973215\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F14%2F2025.02.13.25320514.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=A1994PA16800006\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E15.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-15-1\u0022 title=\u0022View reference 15. in text\u0022 id=\u0022ref-15\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.15\u0022 data-doi=\u002210.1002\/(SICI)1097-0258(19970515)16:9\u0026lt;1017::AID-SIM508\u0026gt;3.0.CO;2-V\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECuzick\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEdwards\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ER\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ESegnan\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EN.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EAdjusting for Non-Compliance and Contamination in Randomized Clinical Trials\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EStat Med\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E1997\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E16\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E9\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E1017\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1029\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1002\/(SICI)1097-0258(19970515)16:9\u0026lt;1017::AID-SIM508\u0026gt;3.0.CO;2-V\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DStatistics%2Bin%2Bmedicine%26rft.stitle%253DStat%2BMed%26rft.aulast%253DCuzick%26rft.auinit1%253DJ.%26rft.volume%253D16%26rft.issue%253D9%26rft.spage%253D1017%26rft.epage%253D1029%26rft.atitle%253DAdjusting%2Bfor%2Bnon-compliance%2Band%2Bcontamination%2Bin%2Brandomized%2Bclinical%2Btrials.%26rft_id%253Dinfo%253Adoi%252F10.1002%252F%2528SICI%25291097-0258%252819970515%252916%253A9%253C1017%253A%253AAID-SIM508%253E3.0.CO%253B2-V%26rft_id%253Dinfo%253Apmid%252F9160496%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1002\/(SICI)1097-0258(19970515)16:9\u0026lt;1017::AID-SIM508\u0026gt;3.0.CO;2-V\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=9160496\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F14%2F2025.02.13.25320514.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=A1997WY90300005\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E16.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-16-1\u0022 title=\u0022View reference 16. in text\u0022 id=\u0022ref-16\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.16\u0022 data-doi=\u002210.1002\/ijc.25278\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EKerkhof\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERoobol\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ECuzick\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EEffect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam)\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EInt J Cancer\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2010\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E127\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E11\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E2639\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E2644\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1002\/ijc.25278\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DInternational%2Bjournal%2Bof%2Bcancer.%2B%2BJournal%2Binternational%2Bdu%2Bcancer%26rft.stitle%253DInt%2BJ%2BCancer%26rft.aulast%253DKerkhof%26rft.auinit1%253DM.%26rft.volume%253D127%26rft.issue%253D11%26rft.spage%253D2639%26rft.epage%253D2644%26rft.atitle%253DEffect%2Bof%2Bthe%2Bcorrection%2Bfor%2Bnoncompliance%2Band%2Bcontamination%2Bon%2Bthe%2Bestimated%2Breduction%2Bof%2Bmetastatic%2Bprostate%2Bcancer%2Bwithin%2Ba%2Brandomized%2Bscreening%2Btrial%2B%2528ERSPC%2Bsection%2BRotterdam%2529.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fijc.25278%26rft_id%253Dinfo%253Apmid%252F20196067%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1002\/ijc.25278\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=20196067\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F14%2F2025.02.13.25320514.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000283609500015\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E17.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-17-1\u0022 title=\u0022View reference 17. in text\u0022 id=\u0022ref-17\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.17\u0022 data-doi=\u002210.1001\/jama.2018.0154\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMartin\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDonovan\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETurner\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EEffect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2018\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E319\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E9\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E883\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E895\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1001\/jama.2018.0154\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJAMA%26rft.volume%253D319%26rft.spage%253D883%26rft_id%253Dinfo%253Adoi%252F10.1001%252Fjama.2018.0154%26rft_id%253Dinfo%253Apmid%252F29509864%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1001\/jama.2018.0154\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=29509864\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F14%2F2025.02.13.25320514.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E18.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-18-1\u0022 title=\u0022View reference 18. in text\u0022 id=\u0022ref-18\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.18\u0022 data-doi=\u002210.1001\/jama.2024.4011\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EMartin\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ERM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETurner\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EEL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EYoung\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EGJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EProstate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJAMA\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2024\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E331\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E17\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E1460\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E1470\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1001\/jama.2024.4011\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJAMA%26rft_id%253Dinfo%253Adoi%252F10.1001%252Fjama.2024.4011%26rft_id%253Dinfo%253Apmid%252F38581198%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1001\/jama.2024.4011\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=38581198\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F14%2F2025.02.13.25320514.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E19.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-19-1\u0022 title=\u0022View reference 19. in text\u0022 id=\u0022ref-19\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.19\u0022 data-doi=\u002210.1007\/s10654-017-0316-1\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EBrooke\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EHL\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ETalb\u00e4ck\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EH\u00f6rnblad\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EThe Swedish cause of death register\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EEur J Epidemiol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2017\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E32\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E9\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E765\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E773\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1007\/s10654-017-0316-1\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DEur%2BJ%2BEpidemiol%26rft.volume%253D32%26rft.spage%253D765%26rft_id%253Dinfo%253Adoi%252F10.1007%252Fs10654-017-0316-1%26rft_id%253Dinfo%253Apmid%252F28983736%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1007\/s10654-017-0316-1\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=28983736\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F14%2F2025.02.13.25320514.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E20.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-20-1\u0022 title=\u0022View reference 20. in text\u0022 id=\u0022ref-20\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.20\u0022 data-doi=\u002210.1080\/00365590802078583\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EFall\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EStr\u00f6mberg\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ERosell\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EJ\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAndr\u00e8n\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EO\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EVarenhorst\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EE\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth cit-collab\u0022\u003ESouth-East Region Prostate Cancer Group\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003EReliability of death certificates in prostate cancer patients\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EScand J Urol Nephrol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2008\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E42\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E4\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E352\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E357\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1080\/00365590802078583\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DScandinavian%2Bjournal%2Bof%2Burology%2Band%2Bnephrology%26rft.stitle%253DScand%2BJ%2BUrol%2BNephrol%26rft.aulast%253DFall%26rft.auinit1%253DK.%26rft.volume%253D42%26rft.issue%253D4%26rft.spage%253D352%26rft.epage%253D357%26rft.atitle%253DReliability%2Bof%2Bdeath%2Bcertificates%2Bin%2Bprostate%2Bcancer%2Bpatients.%26rft_id%253Dinfo%253Adoi%252F10.1080%252F00365590802078583%26rft_id%253Dinfo%253Apmid%252F18609293%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1080\/00365590802078583\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=18609293\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F14%2F2025.02.13.25320514.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000259092300007\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E21.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-21-1\u0022 title=\u0022View reference 21. in text\u0022 id=\u0022ref-21\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.21\u0022 data-doi=\u002210.18637\/jss.v045.i03\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E \u003Cspan class=\u0022cit-name-given-names\u0022\u003EBuuren S\u003C\/span\u003E \u003Cspan class=\u0022cit-name-surname\u0022\u003Evan\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGroothuis-Oudshoorn\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EK.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003Emice: Multivariate Imputation by Chained Equations in R\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EJ Stat Softw\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2011\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E45\u003C\/span\u003E:\u003Cspan class=\u0022cit-fpage\u0022\u003E1\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E67\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.18637\/jss.v045.i03\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DJ%2BStat%2BSoftw%26rft_id%253Dinfo%253Adoi%252F10.18637%252Fjss.v045.i03%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.18637\/jss.v045.i03\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E22.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-22-1\u0022 title=\u0022View reference 22. in text\u0022 id=\u0022ref-22\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.22\u0022 data-doi=\u002210.1111\/j.0006-341X.2000.00554.x\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EGhosh\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ED\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ELin\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EDY\u003C\/span\u003E\u003C\/span\u003E. \u003Cspan class=\u0022cit-article-title\u0022\u003ENonparametric analysis of recurrent events and death\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EBiometrics\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2000\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E56\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E2\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E554\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E562\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1111\/j.0006-341x.2000.00554.x\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DBiometrics%26rft.stitle%253DBiometrics%26rft.aulast%253DGhosh%26rft.auinit1%253DD.%26rft.volume%253D56%26rft.issue%253D2%26rft.spage%253D554%26rft.epage%253D562%26rft.atitle%253DNonparametric%2Banalysis%2Bof%2Brecurrent%2Bevents%2Band%2Bdeath.%26rft_id%253Dinfo%253Adoi%252F10.1111%252Fj.0006-341X.2000.00554.x%26rft_id%253Dinfo%253Apmid%252F10877316%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1111\/j.0006-341X.2000.00554.x\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10877316\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F14%2F2025.02.13.25320514.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=000087677500031\u0026amp;link_type=ISI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-newisilink cit-ref-sprinkles-webofscience\u0022\u003E\u003Cspan\u003EWeb of Science\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E23.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-23-1\u0022 title=\u0022View reference 23. in text\u0022 id=\u0022ref-23\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2025.02.13.25320514v1.23\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003ENordstr\u00f6m\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003ET.\u003C\/span\u003E\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ESTHLM3 MR Phase 2: A New Diagnostic Chain for Prostate Cancer Detection Using the Stockholm3 Test and MR\/Fusion Biopsies\u003C\/span\u003E. \u003Cspan class=\u0022cit-source\u0022\u003Eclinicaltrials.gov; 2023\u003C\/span\u003E. Accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003EDecember 10, 2024\u003C\/span\u003E. \u003Ca href=\u0022https:\/\/clinicaltrials.gov\/study\/NCT03377881\u0022\u003Ehttps:\/\/clinicaltrials.gov\/study\/NCT03377881\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E24.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-24-1\u0022 title=\u0022View reference 24. in text\u0022 id=\u0022ref-24\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-web\u0022 id=\u0022cit-2025.02.13.25320514v1.24\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-source\u0022\u003EMRI-Targeted or Standard Biopsy in Prostate Cancer Screening | New England Journal of Medicine\u003C\/span\u003E. Accessed \u003Cspan class=\u0022cit-date-in-citation\u0022\u003ENovember 5, 2024\u003C\/span\u003E. \u003Ca href=\u0022https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2100852\u0022\u003Ehttps:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2100852\u003C\/a\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E25.\u003C\/span\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal no-rev-xref\u0022 id=\u0022cit-2025.02.13.25320514v1.25\u0022 data-doi=\u002210.1056\/NEJMoa2100852\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EEklund\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EM\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EJ\u00e4derling\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EF\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDiscacciati\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003EMRI-Targeted or Standard Biopsy in Prostate Cancer Screening\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EN Engl J Med\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2021\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E385\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E10\u003C\/span\u003E):\u003Cspan class=\u0022cit-fpage\u0022\u003E908\u003C\/span\u003E\u2013\u003Cspan class=\u0022cit-lpage\u0022\u003E920\u003C\/span\u003E.\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1056\/NEJMoa2100852\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DN%2BEngl%2BJ%2BMed%26rft.volume%253D385%26rft.spage%253D908%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMoa2100852%26rft_id%253Dinfo%253Apmid%252F34237810%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1056\/NEJMoa2100852\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=34237810\u0026amp;link_type=MED\u0026amp;atom=%2Fmedrxiv%2Fearly%2F2025%2F02%2F14%2F2025.02.13.25320514.atom\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-medline\u0022\u003E\u003Cspan\u003EPubMed\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003Cli\u003E\u003Cspan class=\u0022ref-label\u0022\u003E26.\u003C\/span\u003E\u003Ca class=\u0022rev-xref-ref\u0022 href=\u0022#xref-ref-26-1\u0022 title=\u0022View reference 26. in text\u0022 id=\u0022ref-26\u0022\u003E\u21b5\u003C\/a\u003E\u003Cdiv class=\u0022cit ref-cit ref-journal\u0022 id=\u0022cit-2025.02.13.25320514v1.26\u0022 data-doi=\u002210.1016\/j.euo.2024.10.016\u0022\u003E\u003Cdiv class=\u0022cit-metadata\u0022\u003E\u003Ccite\u003E\u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EDiscacciati\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EAbbadi\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EA\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-auth\u0022\u003E\u003Cspan class=\u0022cit-name-surname\u0022\u003EClements\u003C\/span\u003E  \u003Cspan class=\u0022cit-name-given-names\u0022\u003EMS\u003C\/span\u003E\u003C\/span\u003E, \u003Cspan class=\u0022cit-etal\u0022\u003Eet al.\u003C\/span\u003E \u003Cspan class=\u0022cit-article-title\u0022\u003ERepeat Prostate Cancer Screening using Blood-based Risk Prediction or Prostate-specific Antigen in the Era of Magnetic Resonance Imaging\u2013guided Biopsies : A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial\u003C\/span\u003E. \u003Cabbr class=\u0022cit-jnl-abbrev\u0022\u003EEur Urol Oncol\u003C\/abbr\u003E. \u003Cspan class=\u0022cit-pub-date\u0022\u003E2024\u003C\/span\u003E;\u003Cspan class=\u0022cit-vol\u0022\u003E0\u003C\/span\u003E(\u003Cspan class=\u0022cit-issue\u0022\u003E0\u003C\/span\u003E).\u003Cspan class=\u0022cit-pub-id-sep cit-pub-id-doi-sep\u0022\u003E \u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id-scheme\u0022\u003Edoi:\u003C\/span\u003E\u003Cspan class=\u0022cit-pub-id cit-pub-id-doi\u0022\u003E10.1016\/j.euo.2024.10.016\u003C\/span\u003E\u003C\/cite\u003E\u003C\/div\u003E\u003Cdiv class=\u0022cit-extra\u0022\u003E\u003Ca href=\u0022{openurl}?query=rft.jtitle%253DEur%2BUrol%2BOncol%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.euo.2024.10.016%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-openurl cit-ref-sprinkles-open-url\u0022\u003E\u003Cspan\u003EOpenUrl\u003C\/span\u003E\u003C\/a\u003E\u003Ca href=\u0022\/lookup\/external-ref?access_num=10.1016\/j.euo.2024.10.016\u0026amp;link_type=DOI\u0022 class=\u0022cit-ref-sprinkles cit-ref-sprinkles-doi cit-ref-sprinkles-crossref\u0022\u003E\u003Cspan\u003ECrossRef\u003C\/span\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/li\u003E\u003C\/ol\u003E\u003C\/div\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan class=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022https:\/\/www.medrxiv.org\/sites\/default\/files\/js\/js_2xMKaB_ozyQH_X8M4ydhF0QS02D80J6LJ_bdQx4Pl_E.js\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}